JETRO Startup
Global Startup Acceleration Program (GSAP) AlumnisRebirthel Co., Ltd.
CIC '22 Bio/Healthcare
Healthcare Biotech
Rebirthel provides a novel treatment "Allogeneic T cell therapy" using killer T cells regenerated from stem cells. Using stem cells instead of the patient's own cells reduces the patient burden. The cells induced by our patented technologies are universal with higher cytotoxic activity, mass-productivity, and storability. Rebirthel provides the allogeneic T cell therapy “to anyone”, “immediately”, and “at low cost”.
Profile
- Year founded
- 1-Oct-19
- Name of the representative
- Masunori Kajikawa / President and CEO
- HQ location（City)
- Kyoto
- Total amount raised to date
- JPY230,000/USD1.7(as of Dec.2022) (Unit：JPY thousand, USD mio)
- Stage
- Series B
- Major investors/VCs
- Nissai Capital Co., Ltd., FUJIFILM Holdings Corporation, Japan Science and Technology Agency, SCREEN Holdings Co., Ltd., Kagawa Securities Co., Ltd., Toho Holdings Co., Ltd., etc.
- Partnership
- Otsuka Pharmaceutical, etc.
- Major Clients
CEO/Team
*The contents of this page are subject to change without prior notice. Please contact us for the latest information.
